Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mersana Therapeutics Inc (MRSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 238,434
  • Shares Outstanding, K 44,484
  • Annual Sales, $ 10,590 K
  • Annual Income, $ -64,260 K
  • 60-Month Beta 1.74
  • Price/Sales 22.93
  • Price/Cash Flow N/A
  • Price/Book 14.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.03
  • Number of Estimates 6
  • High Estimate 0.48
  • Low Estimate -0.74
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +94.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.85 +40.52%
on 03/06/19
7.65 -29.28%
on 02/25/19
-1.32 (-19.61%)
since 02/15/19
3-Month
2.85 +90.16%
on 01/23/19
7.65 -29.28%
on 02/25/19
+0.90 (+19.96%)
since 12/18/18
52-Week
2.85 +90.16%
on 01/23/19
23.96 -77.42%
on 05/29/18
-12.09 (-69.09%)
since 03/16/18

Most Recent Stories

More News
Mersana Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference

Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 5.41 (+0.93%)
Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Mersana Therapeutics, Inc., (Nasdaq:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 5.41 (+0.93%)
Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2018 Financial Results and Business Updates

Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 5.41 (+0.93%)
Mersana Therapeutics Announces Pricing of Public Offering of Common Stock

Mersana Therapeutics, Inc. (Nasdaq:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 5.41 (+0.93%)
Mersana Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 5.41 (+0.93%)
Mersana Therapeutics Announces Strategic Priorities and Goals for 2019 and Beyond

Company to Focus its Resources on Advancing XMT-1536, its First-in-Class ADC Candidate Targeting NaPi2b, Showing Encouraging Early Signs of Efficacy

MRSN : 5.41 (+0.93%)
Mersana Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 5.41 (+0.93%)
JPM : 107.19 (+0.60%)
Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 5.41 (+0.93%)
Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates

XMT-1536 Phase 1 Dose Escalation Ongoing with Data Expected in the First Half of 2019

MRSN : 5.41 (+0.93%)
Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other...

MRSN : 5.41 (+0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade MRSN with:

Business Summary

Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

2nd Resistance Point 5.63
1st Resistance Point 5.52
Last Price 5.41
1st Support Level 5.28
2nd Support Level 5.14

See More

52-Week High 23.96
Fibonacci 61.8% 15.89
Fibonacci 50% 13.40
Fibonacci 38.2% 10.91
Last Price 5.41
52-Week Low 2.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar